Literature DB >> 16519132

Pulmonary thromboendarterectomy for chronic pulmonary thromboembolism in protein C deficiency.

Masato Yoshida1, Nobuhiko Mukohara, Hidefumi Obo, Nobuchika Ozaki, Tsutomu Shida, Yutaka Okita.   

Abstract

Pulmonary thromboendarterectomy was performed on a patient with chronic pulmonary thromboembolism showing thrombophilia. The patient was a 56-year-old female with the above condition complicated by congenital protein C deficiency. She was admitted to our hospital with severe dyspnea accompanied by right ventricular failure. A pulmonary arteriogram showed occlusion and stenosis from lobar to segmental arteries. Cardiac catheterization showed marked pulmonary hypertension. A lung perfusion scintigram revealed multiple defects in the right and left lungs. After the insertion of an inferior vena cava filter, she was operated on. Following a median sternotomy, thromboendarterectomy of the bilateral pulmonary arteries was performed using deep hypothermia and intermittent circulatory arrest. Circulatory arrest was employed in three periods totaling up to 36 minutes. After surgery, she had improvements in pulmonary hypertension and pulmonary vascular resistance. She maintained improved lung functions, and remained in the New York Heart Association functional class I for more than two years and eight months after surgery.

Entities:  

Mesh:

Year:  2006        PMID: 16519132     DOI: 10.1007/BF02744604

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  10 in total

1.  Long-term outcome after pulmonary thromboendarterectomy.

Authors:  C J Archibald; W R Auger; P F Fedullo; R N Channick; K M Kerr; S W Jamieson; D P Kapelanski; C N Watt; K M Moser
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

Review 2.  Chronic thromboembolic pulmonary hypertension.

Authors:  P F Fedullo; W R Auger; K M Kerr; L J Rubin
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

3.  Surgical treatment of pulmonary hypertension in protein C deficiency.

Authors:  N P Briffa; I Wilson; D B Clarke
Journal:  Br Heart J       Date:  1991-12

4.  Operation for chronic pulmonary thromboembolism accompanied by thrombophilia in 8 patients.

Authors:  M Ando; S Takamoto; Y Okita; R Matsukawa; N Nakanishi; S Kyotani; T Satoh
Journal:  Ann Thorac Surg       Date:  1998-12       Impact factor: 4.330

5.  Risk factors for pulmonary thromboendarterectomy.

Authors:  P O Daily; W P Dembitsky; S Iversen; K M Moser; W Auger
Journal:  J Thorac Cardiovasc Surg       Date:  1990-04       Impact factor: 5.209

6.  Surgical treatment for chronic thromboembolic pulmonary hypertension under profound hypothermia and circulatory arrest in 24 patients.

Authors:  M Ando; Y Okita; O Tagusari; S Kitamura; N Nakanishi; S Kyotani
Journal:  J Card Surg       Date:  1999 Sep-Oct       Impact factor: 1.620

7.  Indications for and the results of pulmonary thromboendarterectomy for thromboembolic pulmonary hypertension.

Authors:  S W Jamieson; K Nomura
Journal:  Semin Vasc Surg       Date:  2000-09       Impact factor: 1.000

8.  Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period.

Authors:  S W Jamieson; W R Auger; P F Fedullo; R N Channick; J M Kriett; R Y Tarazi; K M Moser
Journal:  J Thorac Cardiovasc Surg       Date:  1993-07       Impact factor: 5.209

9.  Chronic pulmonary thromboendarterectomy complicated by antithrombin III deficiency and antiphospholipid syndrome.

Authors:  M Ando; Y Okita; R Matsukawa; S Kitamura
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-11

10.  Hereditary protein C deficiency.

Authors:  A W Broekmans
Journal:  Haemostasis       Date:  1985
  10 in total
  1 in total

1.  The SNPs (-1654C/T, -1641A/G and -1476A/T) of protein C promoter are associated with susceptibility to pulmonary thromboembolism in a Chinese population.

Authors:  Changtai Zhu; Ting Jiang; Yafang Miao; Sugang Gong; Kebin Cheng; Jian Guo; Xiaoyue Tan; Jun Yue; Jinming Liu
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.